Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DUT | P33316 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31637875 | 0.88 | DUT (0.40) | ALDH1A1DUTL3MBTL1 | |
| SCHEMBL4590603 | 0.88 | ALDH1A1 (0.41) | ALDH1A1DUTLMNATSHRSLC22A6 | |
| SCHEMBL4855131 | 0.86 | ALDH1A1 (0.48) | ALDH1A1DUTLMNATSHRSLC22A6 | |
| SCHEMBL13518253 | 0.84 | DUT (0.35) | DUT | |
| SCHEMBL8014066 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNATSHRSLC22A6 | |
| SCHEMBL4844799 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNATSHRSLC22A6 | |
| SCHEMBL30864486 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNATSHRSLC22A6 | |
| SCHEMBL9842173 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNATSHRSLC22A6 | |
| SCHEMBL1930904 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNATSHRSLC22A6 | |
| SCHEMBL7562345 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNATSHRSLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025029890-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| EP-4472966-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| CN-118510762-A | As AMPK activators thiadiazolone derivatives | 贝塔吉能公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| US-20230381132-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| WO-2023150201-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-11279694-B2 | Alvocidib prodrugs and their use as protein kinase inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| EP-3883945-A1 | C11-CYCLIC SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2021105335-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2021-06-03 | — | — | WO | disclosed |
| US-20130231328-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-30 | — | — | US | disclosed |
| EP-0712629-B1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORP (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6348451-B1 | WOUND HEALING AGENTS FOR ANIMALS | PRO-NEURON, INC. | 2002-02-19 | — | — | US | disclosed |
| EP-1166781-A1 | PROTEASOME INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6306834-B1 | METHODS OF TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED BIOLOGICAL DAMAGE, METHODS FOR IMPROVING WOUND HEALING AND TISSUE REPAIR, COMPRISING ADMINISTERING THE COMPOSITIONS OF THE PRESENT INVENTION TO AN ANIMAL. | PRO-NEURON, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-0355131-B1 | ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF | PRO NEURON INC (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0712629-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | PRO-NEURON, INC. (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0355131-A1 | ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF | PRO-NEURON, INC. (US) | 1990-02-28 | — | — | EP | disclosed |
| EP-0297042-A1 | Substituted penem compounds | CIBA-GEIGY AG (CH) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279694-B2 | Alvocidib prodrugs and their use as protein kinase inhibitors | CDK1, CDK2, CDK3 | ALDH1A1 3857/4885DUT 2043/4885LMNA 1619/4885 |
| US-20230381132-A1 | NOVEL COMPOUNDS | CNKSR1, RORC, RCOR3 | ALDH1A1 311/4885DUT 3210/4885LMNA 3991/4885 |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | ALDH1A1 1572/4885DUT 3227/4885LMNA 1142/4885 |
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | IL1R1, LRBA, HCAR1 | ALDH1A1 28/4885DUT 3330/4885LMNA 3277/4885 |
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | UNG, OGG1, NQO1 | ALDH1A1 268/4885DUT 7/4885LMNA 587/4885 |
| US-20130231328-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 4076/4885DUT 2829/4885LMNA 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.